Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

Antibodies

Slava Stamova¹  Stefanie Koristka¹  Juliane Keil¹  Claudia Arndt¹  Anja Feldmann¹  Irene Michalk¹  Holger Bartsch¹  Claudia C. Bippes¹  Marc Schmitz¹  Marc Cartellieri¹ 

[1] Institute of Immunology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany; E-Mails:

关键词: cancer immunotherapy;    monoclonal antibodies;    antibody engineering;    bispecific antibodies;   

DOI  :  10.3390/antib1020172

来源: mdpi

【 摘 要 】

Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.